Phase II Evaluation of VDC-1101 in Canine Cutaneous T-Cell Lymphoma

    Michelle A. Morges, Jenna H. Burton, Corey Saba … Douglas H. Thamm
    Studysummary This study found that the novel drug VDC-1101 showed a 45% objective response rate in treating canine cutaneous T-cell lymphoma, offering a potential treatment option for this challenging disease.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →